Highest-materiality recent filing
OrthoPediatrics files investor presentation for August 2026 meetings; no material new data disclosed
Company filed an investor presentation under Item 7.01 for use in upcoming analyst and investor meetings.
OrthoPediatrics Q2 revenue $70.5M (+15% YoY), raises FY2026 guidance to $265-269M
Q2 2026 revenue $70.5M, up 15% YoY; domestic +14%, international +22%.
OrthoPediatrics shareholders elect directors, approve 2.05M share increase to incentive plan
All four director nominees elected; Dyer had 10.8M for, 8.0M withheld; others >18M for.
OrthoPediatrics Q1 revenue up 13% to $59.4M; lifts FY2026 guidance to $263-267M
Revenue $59.4M (13% YoY); US +11%, International +22%; Trauma & Deformity +14%, Scoliosis +13%.
Company will use the attached investor presentation in upcoming analyst and investor meetings.
OrthoPediatrics adds $20M delayed draw term loan facility via credit agreement amendment
Amendment creates $20M delayed draw term loan facility; draws allowed until June 30, 2027 in minimum $10M increments.
Record FY2025 revenue $236.3M, up 15% from $204.7M in 2024.
OrthoPediatrics files Feb 2026 investor presentation with no material new disclosures
Filing furnishes an investor presentation dated February 2026 for upcoming analyst meetings.
OrthoPediatrics posts record FY2025 revenue $236.1M (+15% YoY); guides FY2026 revenue $262-266M
Q4 2025 revenue $61.3M (+16% YoY); domestic $48.4M (+13%), international $12.9M (+32%).
OrthoPediatrics files investor presentation for upcoming meetings; no material new disclosures
Filing discloses upcoming investor presentations using Exhibit 99.1, a 2026 investor presentation.
Revenue $61.2M, +12% YoY (17% ex-7D capital); Trauma & Deformity +17%, Scoliosis +4%.
OrthoPediatrics files investor presentation for October 2025; no specific financial data disclosed
Filing under Item 7.01 for upcoming investor meetings; presentation slides furnished as Exhibit 99.1.
OrthoPediatrics preliminary Q3 rev $61.2M (+12% YoY); cuts FY guidance to $233.5-$234.5M
Preliminary Q3 net revenue $61.2M, up 12% YoY; domestic $48.7M (+14%), international $12.5M (+6%).
OrthoPediatrics board member Schlotterback retires; Kelly Fischer appointed
Terry Schlotterback resigned from Board effective Aug. 8, 2025, due to retirement; no disagreement.
OrthoPediatrics expands specialty bracing into California, Ohio, Colorado, New York, and Ireland
First OPSB clinic in California opens in Los Angeles market, providing access to millions of potential patients.
OrthoPediatrics Q2 revenue hits record $61.1M (+16% YoY); raises FY2025 guidance
Revenue of $61.1M (+16% YoY); domestic up 17%, international up 12%.
OrthoPediatrics files August 2025 investor presentation; no specific metrics disclosed
Investor presentation filed as Exhibit 99.1 with no financial results or operational updates in the filing text.
Elected four directors: Fred L. Hite (17.1M for), Bryan W. Hughes (18.0M for), Samuel D. Riccitelli (11.5M for), Mark C. Throdahl (16.3M for); note significant withheld votes for Riccitelli (7.7M).
OrthoPediatrics amends Medtech Concepts acquisition; remaining $3.75M due in stock instead of cash
First Amendment replaces three $1.25M cash earn-outs with unregistered common stock installments.
OrthoPediatrics Q1 revenue $52.4M (+17% YoY); raises FY2025 guidance to $236-242M
Total Q1 revenue $52.4M (+17% YoY); U.S. revenue $40.9M (+19%), international $11.5M (+11%).
OrthoPediatrics files May 2025 investor presentation; no material new details
Presentation furnished as Exhibit 99.1 for upcoming analyst and investor meetings.
OrthoPediatrics files investor presentation with no new material information
Filing announces upcoming investor presentations using Exhibit 99.1.
Full year 2024 revenue $204.7M, up 38% from $148.7M in 2023; Q4 revenue $52.7M, up 40% YoY.
OrthoPediatrics files investor presentation for upcoming meetings, no financial details disclosed
Company filed a Regulation FD disclosure (Item 7.01) regarding upcoming investor and analyst presentations.
OrthoPediatrics reports record FY2024 revenue of $204.7M (+38% YoY), issues 2025 guidance
Preliminary unaudited FY2024 revenue $204.7M, up 38% from $148.7M in 2023.
Executive officers will use the presentation in upcoming meetings with analysts and investors.
OrthoPediatrics Q3 record revenue $54.6M (+37% YoY); raises FY guidance to $202-204M
Revenue $54.6M (+37% YoY); domestic up 45%, international up 12%.
OrthoPediatrics inks new employment pacts with CEO, CFO, and three other NEOs
CEO Bailey base salary $550k; CFO Hite $501k; Odle/Gerritzen $368k; Hauser $400k.
OrthoPediatrics holds Investor Day on Sept 12, 2024; notes >1M kids helped
Investor Day presentation on September 12, 2024 with investor and analyst meetings.
OrthoPediatrics closes $25M term loan and $50M convertible notes issuance
$25M term loan from Braidwell LP funded on August 12, 2024.
OrthoPediatrics provides investor presentation for August 2024; details not disclosed in filing.
Company furnished an investor presentation dated August 2024 for use in meetings with investors and analysts.
Term loan at SOFR + 6.50% (PIK option adds 1.00%), interest-only until August 2029 maturity.
OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M
Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.
OrthoPediatrics stockholders approve 2024 Incentive Award Plan, replacing 2017 plan
Board adopted the 2024 Incentive Award Plan on Feb 29, 2024, with stockholder approval obtained on May 24, 2024.
OrthoPediatrics stockholders elect directors, approve compensation and incentive plan
David R. Bailey, Marie C. Infante, Jimmy D. McDonald elected as directors with 91.1%, 63.8%, 71.4% of votes cast respectively.
Company furnished an investor presentation (Exhibit 99.1) for upcoming analyst and investor meetings.
OrthoPediatrics Q1 revenue up 41% to $44.7M; raises FY 2024 guidance to $200-203M
Total revenue $44.7M (+41% YoY); U.S. +44%, international +33%.
OrthoPediatrics furnishes March 2024 investor presentation; no new financial data disclosed
Investor presentation dated March 2024 furnished under Item 7.01 for upcoming analyst meetings.
OrthoPediatrics FY 2023 revenue $148.7M (+22% YoY); guides FY 2024 rev $197-200M
FY 2023 net loss $21.0M ($0.92/share) vs net income $1.3M ($0.06) in 2022; adjusted EBITDA rose to $5.0M from $0.2M.
Acquired Boston O&P for $22M upfront cash plus ~83,000 restricted shares (~$2.5M) to employees.
OrthoPediatrics prelim Q4 revenue $37.6M (+21%); acquires Boston O&P; 2024 guidance $197-200M
Preliminary Q4 2023 net revenue $37.6M (up 21% YoY); full year $148.7M (up 22%).
OrthoPediatrics enters $80M credit facility with MidCap; $10M term loan drawn
Term loan facility up to $30M (three $10M tranches); first tranche of $10M funded at closing.
Presentation used in discussions with investors and analysts.
OrthoPediatrics board adopts annual Say-on-Pay votes after shareholder preference
Shareholders voted non-binding preference for annual Say-on-Pay frequency at June 14, 2023 meeting.
OrthoPediatrics amends Bylaws to adopt universal proxy card rules and enhance disclosure
Board approved amended and restated Bylaws effective November 2, 2023.
OrthoPediatrics reports record Q3 revenue of $40.0M, up 14% YoY; raises adj. EBITDA guidance
Total revenue $40.0M (+14% YoY); U.S. revenue $29.4M (+11%), international $10.6M (+26%).
OrthoPediatrics files August 2023 investor presentation; no material financial updates
Company provided its standard investor presentation for upcoming meetings with analysts and investors.
OrthoPediatrics Q2 revenue $39.6M (+20% YoY); net loss $2.9M, FY guide reaffirmed
Total revenue $39.6M, +20% vs $32.9M in Q2 2022; US +19%, international +25%.
All four stockholder proposals approved at OrthoPediatrics 2023 annual meeting
Directors elected: Dyer (20.2M for), Pelizzon (15.7M for, 4.7M withheld), Ruf (15.7M for), Schlotterback (14.4M for).
OrthoPediatrics files May 2023 investor presentation; specific data not included in filing text
Filing contains an investor presentation dated May 2023 furnished under Item 7.01.
On April 27, 2023, the Board accepted the resignation of Kevin Unger as a member of the Board, which became effective April 28, 2023.
Also effective April 28, 2023, the Board appointed George S. M. Dyer, MD, to fill the vacancy caused by Mr. Unger’s departure and to serve in the class of directors whose terms expire at the annual stockholder meeting in 2023.
Effective October 18, 2022, Stephen F. Burns retired from the OrthoPediatrics Corp. (the “Company”) Board of Directors.
effective October 18, 2022, the Board appointed Jimmy D. McDonald to fill the vacancy caused by Mr. Burns’ retirement to serve in the class of directors whose terms expire at the annual shareholder meeting in 2024.
Effective November 3, 2021, Bernie Berry, III has retired from the Company's Board of Directors after twelve years of service.
The Board has appointed David R. Bailey, the Company’s President and Chief Executive Officer, to fill the vacancy caused by Mr. Berry’s retirement to serve in the Class of Directors whose terms expire at the annual shareholder meeting in 2024.
Max materiality 0.80 · Median 0.35 · Most common event earnings